Health
Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy – News-Medical.net
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB…
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit assessment, the German Institute for Quality and Efficiency in Health…
Continue Reading
